Unknown

Dataset Information

Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.


ABSTRACT:

Purpose

Tepotinib is a highly selective, potent, mesenchymal-epithelial transition factor (MET) inhibitor, approved for the treatment of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping. Objectives of this population pharmacokinetic (PK) analysis were to evaluate the dose-exposure relationship of tepotinib and its major circulating metabolite, MSC2571109A, and to identify the intrinsic/extrinsic factors that are predictive of PK variability.

Methods

Data were included from 12 studies in patients with cancer and in healthy participants. A sequential modeling approach was used to analyze the parent and metabolite data, including covariate analyses. Potential associations between observed covariates and PK parameters were illustrated using bootstrap analysis-ba

SUBMITTER: Xiong W 

PROVIDER: S-EPMC9054876 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature